Anti-Infective Drugs Market, By Drug Class (Antibacterial, Antifungals, Antiparasitics, and Antivirals), By Indication, By Route of Administration, By End-User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4425
|
Published Date
November 2025
|
Pages
378
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
The Anti-Infective Drugs Market size was valued at US$ 134,267.21 Million in 2024, expanding at a CAGR of 3.1% from 2025 to 2032.
The anti-infective drugs market centers on the development and distribution of medications designed to prevent and treat infections caused by bacteria, viruses, fungi, and parasites. The growing prevalence of hospital-acquired infections and the rapid rise of antibiotic resistance have prompted major pharmaceutical companies such as Pfizer and GlaxoSmithKline to expand their research and development pipelines for novel antimicrobials. According to the World Health Organization (WHO), more than 4.95 million deaths in 2023 were associated with drug-resistant bacterial infections, underscoring the urgent need for advanced therapeutic solutions.
Collaborations between biotechnology firms and academic institutions are driving innovation in next-generation antibiotics and antiviral treatments. Nevertheless, high development costs and diminishing profitability in the antibiotics segment continue to deter smaller companies from entering the market. Despite these challenges, expanding access to treatments in emerging economies and the growing emphasis on combination therapies present significant opportunities for market players to diversify their product portfolios and enhance patient outcomes.
Anti-Infective Drugs Market- Market Dynamics
Rising Infection Rates and Antimicrobial Resistance Drive Innovation in the Anti-Infective Drug Market
Rising infection rates and escalating antimicrobial resistance are prompting global health agencies and pharmaceutical companies to accelerate innovation in anti-infective drugs. According to the World Health Organization (WHO), antimicrobial resistance directly caused approximately 1.27 million deaths annually, with an additional 3.68 million deaths associated with drug-resistant infections. In response, organizations such as the U.S. Centers for Disease Control and Prevention (CDC) are funding initiatives to develop rapid diagnostic tools and novel antibiotics. Governments worldwide are also supporting public–private partnerships, including the AMR Action Fund, to revitalize the diminishing antibiotic pipeline. These coordinated efforts are driving the advancement of new classes of antimicrobials, targeted antiviral therapies, and combination treatments aimed at combating resistant pathogens more effectively.
Anti-Infective Drugs Market- Segmentation Analysis:
The Global Anti-Infective Drugs Market is segmented on the basis of Drug Class, Indication, Route of Administration, End-User, and Region.
The global anti-infective market is categorized into four main drug classes: antibacterials, antivirals, antifungals, and antiparasitics. Antibacterials dominate due to their extensive use in treating common and hospital-acquired bacterial infections. According to the World Health Organization (WHO), bacterial infections account for one in eight global deaths, underscoring the persistent demand for antibiotic therapies. Market reports estimate that the global antibacterial drugs segment was valued at approximately USD 46.8 billion in 2024 and is projected to reach nearly USD 58.6 billion by 2030, supported by strong government initiatives promoting antibiotic stewardship. Antivirals hold the second-largest share, fueled by increasing viral outbreaks such as influenza, hepatitis, and emerging coronaviruses. The global antiviral drugs market is forecasted to reach around USD 62 billion by 2030, with WHO reporting that viral infections continue to cause over 2.5 million deaths annually worldwide. Antifungals rank next, driven by a surge in invasive fungal infections and the rising prevalence of immunocompromised patients. WHO’s 2022 fungal priority pathogens list highlights over 6.5 million global cases of invasive fungal disease and 3.8 million related deaths each year. Antiparasitics form a smaller but crucial niche, particularly in low- and middle-income countries where malaria and neglected tropical diseases remain endemic; WHO reports that malaria alone caused an estimated 608,000 deaths in 2022, prompting continuous government funding for antiparasitic drug development.
When segmented by indication, the market includes nine key categories: pneumonia, sepsis, tuberculosis, dermatophytosis, candidiasis, hepatitis virus infection, HIV infection, COVID-19 virus, and methicillin-resistant Staphylococcus aureus (MRSA). Pneumonia leads globally, as it remains a top cause of mortality; WHO data show it killed around 740,000 children under five in 2019, representing 14% of all deaths in that group. Sepsis follows, with WHO estimating nearly 49 million annual cases and 11 million deaths worldwide, reflecting growing critical-care demand. HIV and hepatitis infections continue to hold significant shares due to sustained international treatment programs — about 40.8 million people were living with HIV in 2024, and viral hepatitis causes roughly 1.3 million deaths each year. Tuberculosis and MRSA drive ongoing antibiotic research and innovation, as drug resistance remains a global health emergency; WHO recorded 10.6 million TB cases in 2022. Candidiasis and dermatophytosis constitute targeted antifungal markets, with the Centers for Disease Control and Prevention (CDC) noting a steady rise in Candida auris infections globally. COVID-19, though declining in prevalence, continues to represent a specialized antiviral therapy segment, with governments maintaining pandemic preparedness funding through initiatives such as WHO’s Global Health Emergency Corps.
Anti-Infective Drugs Market- Geographical Insights
North America leads the global anti-infective drugs market, supported by a strong healthcare infrastructure, advanced research capabilities, and substantial R&D investments from key players such as Pfizer and Merck. In 2018, Pfizer collaborated with BioNTech to expand mRNA-based anti-infective applications beyond COVID-19, further strengthening its regional presence. Europe follows closely, driven by EU-funded antimicrobial resistance (AMR) initiatives and strategic collaborations such as GSK’s partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop novel antibiotics. Asia-Pacific is emerging as a significant growth hub, fueled by increasing infection rates and proactive government initiatives to improve access to treatment. For example, India’s National Action Plan on AMR promotes antibiotic stewardship, surveillance, and local production to reduce dependency on imports. Latin America and the Middle East & Africa (MEA) regions are witnessing growing vaccine adoption and public health awareness campaigns, contributing to gradual market expansion and improved infection management.
The United States dominates the North American anti-infective drugs market due to its advanced healthcare infrastructure and robust clinical research ecosystem. In 2024, Merck acquired Prometheus Biosciences to strengthen its immunology and infectious disease portfolio, enhancing R&D capabilities. The Biomedical Advanced Research and Development Authority (BARDA) continues to fund partnerships with companies such as GSK and Venatorx Pharmaceuticals to accelerate antibiotic development. The increasing prevalence of multidrug-resistant infections, as reported by the Centers for Disease Control and Prevention (CDC), is driving hospitals to adopt innovative therapies and diagnostic technologies. Moreover, strong regulatory frameworks established by the U.S. Food and Drug Administration (FDA) and incentive programs such as the Generating Antibiotic Incentives Now (GAIN) Act continue to encourage innovation and commercialization of new anti-infective therapies.
Anti-Infective Drugs Market- Competitive Landscape:
The competitive landscape of the anti-infective drugs market is defined by major players including Pfizer, Merck, GSK, Johnson & Johnson, and Roche, who are expanding their portfolios through sustained R&D investments and strategic collaborations. In 2020, Pfizer partnered with Gilead Sciences to co-develop new antiviral combinations targeting resistant infections, while GSK’s ongoing collaboration with BARDA focuses on next-generation antibiotic development. Johnson & Johnson is investing in bacteriophage research to combat antibiotic-resistant “superbugs,” and smaller biotechnology firms such as Venatorx Pharmaceuticals and Iterum Therapeutics are partnering with larger pharmaceutical companies to scale manufacturing and enhance global distribution. Collectively, these partnerships, acquisitions, and government-backed initiatives are intensifying competition and driving rapid innovation across the anti-infective sector.
Recent Developments
- February 2025: The Mérieux Foundation, SPIM, and the World Health Organization (WHO) launched a new Guide to Prescribing Anti-Infective Drugs in Madagascar. The updated guide includes revised antibiotic chapters, enhanced diagnostic guidance, and integration of WHO’s 2023 AWaRe classification, supporting standardized prescribing practices and strengthening national AMR action plans.
- February 2025: The U.S. FDA approved EMBLAVEO™ (aztreonam + avibactam) for adult patients with complicated intra-abdominal infections, including those caused by E. coli and Klebsiella species, where few or no effective treatment options exist.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTI-INFECTIVE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie
- AstraZeneca
- Bayer
- Cipla
- Dr. Reddy’s Laboratories
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Glenmark Pharmaceuticals
- Johnson & Johnson
- Lupin
- Merck & Co.
- Novartis
- Pfizer
- Roche
- Sandoz (Novartis)
- Sanofi
- Sun Pharmaceutical Industries
- Teva Pharmaceutical Industries
- Viatris
- ViiV Healthcare
- Others
GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Antibacterial
- B-Lactams
- Quinolones
- Macrolides
- Tetracycline
- Aminoglycoside
- Others
- Antifungals
- Azoles
- Echinocandins
- Polyenes
- Antiparasitics
- Antivirals
GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Pneumonia
- Sepsis
- Tuberculosis
- Dermatophytosis
- Candidiasis
- Hepatitis virus infection
- HIV infection
- Covid-19 Virus
- Methicillin-resistant Staphylococcus Aureus
- Others
GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Oral
- Injectable
- Topical
- Inhalation
GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Clinics
- Retail Pharmacies
- Institutional Buyers
GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Anti-Infective Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Anti-Infective Drugs Market Snippet by Drug Class
2.1.2. Anti-Infective Drugs Market Snippet by Indication
2.1.3. Anti-Infective Drugs Market Snippet by Route of Administration
2.1.4. Anti-Infective Drugs Market Snippet by End-User
2.1.5. Anti-Infective Drugs Market Snippet by Country
2.1.6. Anti-Infective Drugs Market Snippet by Region
2.2. Competitive Insights
3. Anti-Infective Drugs Key Market Trends
3.1. Anti-Infective Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Anti-Infective Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Anti-Infective Drugs Market Opportunities
3.4. Anti-Infective Drugs Market Future Trends
4. Anti-Infective Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Anti-Infective Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Anti-Infective Drugs Market Landscape
6.1. Anti-Infective Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Anti-Infective Drugs Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
7.1.2. Antibacterial
7.1.2.1. B-Lactams
7.1.2.2. Quinolones
7.1.2.3. Macrolides
7.1.2.4. Tetracycline
7.1.2.5. Aminoglycoside
7.1.2.6. Others
7.1.3. Antifungals
7.1.3.1. Azoles
7.1.3.2. Echinocandins
7.1.3.3. Polyenes
7.1.4. Antiparasitics
7.1.5. Antivirals
8. Anti-Infective Drugs Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
8.1.2. Pneumonia
8.1.3. Sepsis
8.1.4. Tuberculosis
8.1.5. Dermatophytosis
8.1.6. Candidiasis
8.1.7. Hepatitis virus infection
8.1.8. HIV infection
8.1.9. Covid-19 Virus
8.1.10. Methicilin-resistant Staphylococcus Aureus
8.1.11. Others
9. Anti-Infective Drugs Market – By Route of Administration
9.1. Overview
9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
9.1.2. Oral
9.1.3. Injectable
9.1.4. Topical
9.1.5. Inhalation
10. Anti-Infective Drugs Market – By End-User
10.1. Overview
10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
10.1.2. Hospitals
10.1.3. Clinics
10.1.4. Retail Pharmacies
10.1.5. Institutional Buyers
11. Anti-Infective Drugs Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Anti-Infective Drugs Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Anti-Infective Drugs Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Anti-Infective Drugs Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Anti-Infective Drugs Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Anti-Infective Drugs Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Anti-Infective Drugs Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. AbbVie
12.2.2. AstraZeneca
12.2.3. Bayer
12.2.4. Cipla
12.2.5. Dr. Reddy’s Laboratories
12.2.6. Gilead Sciences
12.2.7. GlaxoSmithKline (GSK)
12.2.8. Glenmark Pharmaceuticals
12.2.9. Johnson & Johnson
12.2.10. Lupin
12.2.11. Merck & Co.
12.2.12. Novartis
12.2.13. Pfizer
12.2.14. Roche
12.2.15. Sandoz (Novartis)
12.2.16. Sanofi
12.2.17. Sun Pharmaceutical Industries
12.2.18. Teva Pharmaceutical Industries
12.2.19. Viatris
12.2.20. ViiV Healthcare
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
